Day One Biopharmaceuticals (NASDAQ:DAWN – Get Rating) had its target price upped by The Goldman Sachs Group from $45.00 to $62.00 in a research note issued to investors on Monday, Benzinga reports. The brokerage currently has a buy rating on the stock.
Other equities analysts also recently issued research reports about the stock. Bank of America began coverage on shares of Day One Biopharmaceuticals in a research note on Thursday, December 1st. They issued a buy rating and a $34.00 price target for the company. HC Wainwright boosted their target price on Day One Biopharmaceuticals from $35.00 to $45.00 and gave the stock a buy rating in a research note on Monday. Piper Sandler upped their price target on Day One Biopharmaceuticals from $40.00 to $45.00 and gave the stock an overweight rating in a report on Sunday. Finally, Needham & Company LLC initiated coverage on Day One Biopharmaceuticals in a research note on Wednesday, December 14th. They issued a buy rating and a $40.00 price objective for the company. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Day One Biopharmaceuticals presently has an average rating of Buy and an average price target of $43.50.
Day One Biopharmaceuticals Stock Up 2.6 %
NASDAQ DAWN opened at $21.89 on Monday. The stock has a 50-day moving average of $20.75 and a two-hundred day moving average of $20.79. Day One Biopharmaceuticals has a 1-year low of $5.44 and a 1-year high of $28.35.
Insider Buying and Selling at Day One Biopharmaceuticals
In other news, insider Samuel C. Blackman sold 10,000 shares of the stock in a transaction dated Thursday, December 1st. The stock was sold at an average price of $21.45, for a total value of $214,500.00. Following the transaction, the insider now owns 1,260,148 shares in the company, valued at approximately $27,030,174.60. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. In related news, Director Julie Papanek Grant sold 5,000 shares of Day One Biopharmaceuticals stock in a transaction on Tuesday, November 1st. The shares were sold at an average price of $20.04, for a total transaction of $100,200.00. Following the sale, the director now directly owns 424,358 shares in the company, valued at approximately $8,504,134.32. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Samuel C. Blackman sold 10,000 shares of the business’s stock in a transaction on Thursday, December 1st. The shares were sold at an average price of $21.45, for a total transaction of $214,500.00. Following the completion of the sale, the insider now directly owns 1,260,148 shares of the company’s stock, valued at $27,030,174.60. The disclosure for this sale can be found here. Insiders have sold a total of 119,178 shares of company stock worth $2,458,187 over the last ninety days. Corporate insiders own 8.70% of the company’s stock.
Institutional Trading of Day One Biopharmaceuticals
Hedge funds and other institutional investors have recently made changes to their positions in the company. Amalgamated Bank acquired a new stake in shares of Day One Biopharmaceuticals in the 1st quarter valued at about $30,000. ACG Wealth purchased a new stake in Day One Biopharmaceuticals in the second quarter valued at approximately $32,000. TCI Wealth Advisors Inc. purchased a new stake in Day One Biopharmaceuticals in the second quarter valued at approximately $35,000. Quantbot Technologies LP acquired a new stake in shares of Day One Biopharmaceuticals in the second quarter valued at approximately $51,000. Finally, UBS Group AG purchased a new position in shares of Day One Biopharmaceuticals during the second quarter worth approximately $69,000. Institutional investors and hedge funds own 86.08% of the company’s stock.
Day One Biopharmaceuticals Company Profile
Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/progressive low-grade glioma.
- Get a free copy of the StockNews.com research report on Day One Biopharmaceuticals (DAWN)
- Does TJX Have More Room To Run Or Will It Sink Into New Base?
- What Does Amazon’s Acquisition of 1LifeMedical Mean To Investors?
- Why Wall Street Has Bullish Targets on Target Stock
- 3 Airline Stocks Taking Off in 2023
- What Macy’s Guidance Means For Retail
Receive News & Ratings for Day One Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Day One Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.